From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Related Posts
Cancer Core Europe´s information hub: website now launched to update on the very latest from this inspired multi-center partnership
Launched in the Autumn of 2014, Cancer Core Europe is a working consortium that represents a critical mass of activity…
20 May 2016
WIN Consortium and Oracle Join Forces to Accelerate Personalized Cancer Care
The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium, of which the Vall d´Hebron Institute of Oncology (VHIO) is…
18 Oct 2012
Nature Reviews Cancer: sponsor of Poster Prizes at VHIO´s Symposium Towards Predictive Cancer Models
News just in: as a reflection of the scientific program of excellence of VHIO´s forthcoming Special Symposium Towards Predictive Cancer…
24 Feb 2016
Novel bispecific agent as mono or in combo with paired immunotherapy promises increased therapeutic efficacy against metastatic colorectal cancer
Novel bispecific antibody that simultaneously binds to the carcinoembryonic antigen (CEA) and lymphocytes triggers immune response in patients with metastatic…
05 Jun 2017
José Baselga is awarded the prize Jaime I in Medical Research in Alicante
According to the Director of VHIO, “the race in research against cancer has only just begun”
07 Sep 2010
Genomic study leads to classification of fibroepithelial breast cancer and predicts tumor cell behavior
The study, led by VHIO, is the first to use gene expression to classify fibroepithelial tumors Genomic discovery reveals decisively…
18 Mar 2015
Oncology channel ecancer catches up with VHIO´s Elena Garralda and Cristina Saura during last week´s ESMO Congress
During last week´s ESMO Congress celebrated in Madrid 08 – 12 September, oncology channel ecancer TV interviewed Elena Garralda, Executive…
14 Sep 2017
Academy recognition of VHIO´s Director, Josep Tabernero, for his exceptional leadership and contribution to medical oncology, cancer science, and patient care
Announced this week, Josep Tabernero, Director of VHIO, Head of the Medical Oncology Service of the Vall d´Hebron University Hospital…
16 Feb 2017
Spanish periodical EL MUNDO reveals its top 25 of the most influential Spanish Citizens in Medicine for 2014
Each year, in January, the Spanish periodical EL MUNDO publishes its selection of the 500 most influential Spanish citizens for that…
10 Jan 2014
Promoting connectivity and exchange between young cancer researchers and clinicians: ESMO YOs meet the EACR
Celebrated at the recent 2014 Congress of the European Society for Medical Oncology (ESMO), 26 – 28 September (Madrid, Spain),…
06 Nov 2014
Pharmacological drugs under investigation show effect on tumor-initiating cells
The group led by Dr Joan Seoane, ICREA Research Professor at the VHIO, has carried out the research in glioma, the most common malignant brain tumor. The study published describes how to identify cells with characteristics of stem cells in the interior of the glioma. These cells, known as Glioma initiating cells (GICs), are responsible for initiating the glioma and also for it reappearing after surgical removal.
13 Dec 2010
International study published in The Lancet shows efficacy of new gastric cancer drug
The phase III study, published in the prestigious scientific journal, The Lancet, in which researchers at the Vall d´Hebron University…
03 Oct 2013
Therapeutic targets for cancer
Arkaitz Carracedo, from the Harvard Medical School, gives a lecture on the latest developments on potential therapy for cancer
07 Sep 2010
Liquid biopsy of cerebrospinal fluid for less invasive, more effective ´policing´ of brain tumors
VHIO leads research proposing cerebrospinal fluid (CSF) as liquid biopsy for the early diagnosis, prognosis, therapeutic management and tracking of…
10 Nov 2015
VHIO collaborates in European, multi-center study aimed at reducing side-effects of radiotherapy
Supported by the European Commission´s 7th Framework Programme of Research and Development, and coordinated by Catharine West, University of Manchester,…
13 Jan 2014
